Hangzhou AGS MedTech Co. Ltd. A (688581) — Capital Reinvestment Ratio

Latest as of December 2025: 0.42x

Hangzhou AGS MedTech Co. Ltd. A (688581) has a Capital Reinvestment Ratio of 0.42x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥151.20 Million) in capital expenditures (CN¥63.47 Million). See 688581 equity to assets ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.42x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥151.20 Million
CNY

Capital Expenditures

CN¥63.47 Million
CNY

Data as of

Dec 2025
Most recent filing

Hangzhou AGS MedTech Co. Ltd. A Capital Reinvestment Ratio (2021–2025)

This chart tracks Hangzhou AGS MedTech Co. Ltd. A's Capital Reinvestment Ratio across 5 annual periods. Check Hangzhou AGS MedTech Co. Ltd. A total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Hangzhou AGS MedTech Co. Ltd. A (2021–2025)

Year-by-year Capital Reinvestment Ratio for Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2025. For live market cap and broader valuation context, see Hangzhou AGS MedTech Co. Ltd. A (688581) total market value.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.42x CN¥151.20 Million CN¥63.47 Million ▲ +167.2%
2024 0.16x CN¥315.80 Million CN¥49.60 Million ▼ -32.6%
2023 0.23x CN¥221.45 Million CN¥51.57 Million ▼ -39.4%
2022 0.38x CN¥156.38 Million CN¥60.12 Million ▲ +190.3%
2021 0.13x CN¥118.25 Million CN¥15.66 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow